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Abstract
Purpose Cardiovascular diseases (CVDs) are a leading cause of morbidity and mortality worldwide, necessitating major efforts
in prevention. This review summarizes the currently available training opportunities in CVD prevention for fellows-in-training
(FITs) and residents. We also highlight the challenges and future directions for CVD prevention as a field and propose a structure
for an inclusive CVD prevention training program.
Recent Findings At present, there is a lack of centralized training resources for FITs and residents interested in pursuing a career
in CVD prevention. Training in CVD prevention is not an accredited subspecialty fellowship by the American Council of
Graduate Medical Education (ACGME). Although there are several independent training programs under the broad umbrella
of CVD prevention focusing on different aspects of prevention, there is no unified curriculum or training.
Summary More collaborative efforts are needed to identify CVD prevention as an ACGME-accredited subspecialty fellowship.
Providing more resources can encourage and produce more leaders in this essential field.
Keywords Heart disease prevention . CVD prevention training . Cardiology training programs . Preventive cardiology training .
Fellowship . Fellows-in-training
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Approximately 2200 Americans die from cardiovascular disease (CVD)-related causes each day, an average of 1 death
every 40 s [1]. According to the 2017 heart disease and stroke
statistics update by the American Heart Association (AHA),
about 92.1 million American adults are living with some form
of CVD including coronary heart diseases (CHDs) or strokes.
There is also an alarming increase in the incidence of CHD
among younger adults [1]. The annual direct and indirect costs
from CHD and stroke is estimated to total more than $316
billion when including both health expenditures and lost
productivity.
There is robust evidence that CVD is a potentially modifiable disease. Although atherosclerosis is a life-long process,
risk factor modification helps with the prevention of CVD
events and associated morbidities. Additionally, with the
ever-growing need for cost-efficient delivery of care and introduction of quality payment programs, most notably the
Medicare and CHIP Reauthorization (MACRA) Act 2015,
the focus has shifted to high-quality care at a low cost.
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Preventive strategies have been shown to have the lowest cost
per quality-adjusted life-years [2].
Data also suggest that many patients who are at high
risk of CVD or those with established coronary diseases or
strokes remain unidentified and/or inadequately treated
[3]. Pokharel et al. have previously shown suboptimal
statin use and facility-level variation in statin prescriptions
for patients at high risk for CHD [3]. Results from the
PINN ACLE (Practice INNovation And CLinical
Excellence) registry, a national cardiology outpatient quality improvement registry which extracts data from electronic medical records, revealed that approximately 38%
of patients with diabetes in cardiology practices had no
documentation of a statin prescription [4]. We know that
individuals with familial hypercholesterolemia (FH), if untreated, are at least 20 times more likely to have incident
CHD events than those without FH [5]. Early crosssectional data from the national FH registry (CASCADEFH) showed that the median age of diagnosis for adults
with FH in the USA was 47 years [3]. Currently, not only
are individuals with FH likely to be diagnosed very late in
life but also under-treated, with only 25% patients in the
CASCADE-FH registry reaching low-density lipoprotein
cholesterol levels < 100 mg/dL [3]. A recent study showed
subclinical atherosclerosis can be detected by ultrasonography and coronary calcium tests in a cohort of middleaged individuals without traditional risk factors for CVD
[6]; highlighting the potential need for early risk stratification [7]. Education in CVD prevention including familiarity and use of newer diagnostic modalities are key to a
more comprehensive detection of high-risk CVD populations. Newer biomarkers such as high-sensitivity troponin
T and N-terminal pro brain natriuretic peptide (NTproBNP) measured by very sensitive assays can diagnose
subclinical myocardial injury, and these biomarkers have
been shown to improve risk prediction of coronary heart
diseases and heart failure. Use of coronary artery calcium
scoring has been established as a diagnostic marker for
subclinical atherosclerosis. Thus, a number of diagnostic
modalities have a potential to be highly useful in clinical
practices for CVD prevention.
Cardiologists and primary care providers have a crucial
role to play in prevention of CVD events; by first and foremost, identifying high-risk individuals, then applying lifestyle interventions and pharmacotherapies, and coordinating multidisciplinary care, including cardiac rehabilitation,
when indicated. However, most of the experience in this
field comes “on the fly” while training. Currently, there is
a lack of strategically designed subspecialty training in
CVD prevention. Further, there is an absence of consensus
on the necessary curriculum for training programs as well
as a lack of a centralized resources for CVD prevention
training programs [8••].
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In this article, we review available resources for CVD prevention training. Further, we highlight the leading challenges
for training in this niche area of CVD prevention.

Status of Cardiovascular Disease Prevention Training
in the USA
Over the last two decades, there has been incremental growth
in our understanding of CVD risk factors. Hence, there has
been a rapid influx of newer guidelines related to lipids, hypertension, diabetes mellitus, obesity, thrombosis, and vascular diseases. As a result, various independently funded fellowships have emerged with a focus on these specific disciplines,
aimed at providing advanced training.
In 2012, a survey of the US cardiology fellowship training
programs revealed that only 24% of the surveyed programs
met the Core Cardiovascular Training Symposium
(COCATS) guidelines with a dedicated 1-month rotation in
preventive cardiology (used interchangeably with CVD prevention). Approximately, 24% of the programs had no formalized training in CVD prevention and 30% had no faculty with
expertise in the field [9]. “Lack of time” and “lack of a developed curriculum in prevention” were cited as the most prominent barriers to training in CVD prevention by program directors and chief fellows of the surveyed programs [9].
Following this survey, the COCATS 4 Task Force 2 guidelines were published in 2015 and endorsed by the American
board of Internal Medicine (ABIM) and Accreditation
Council of Graduate Medical Education (ACGME) [3]. This
document recognized primary and secondary atherosclerotic
CVD prevention strategies as core learning principles during
general cardiology fellowship training. As with most other
adult CVD areas, three levels of training were described and
are currently applicable [10••], as follows:
&

Level 1: Basic training required for all physicians to become competent cardiologists. This level of training can
be achieved by at least 1 month of training dedicated to
CVD prevention medicine. This 1-month rotation should
encompass weekly attendance at a cardiac rehabilitation
program, diabetes or endocrinology clinic, hypertension
clinic, and dyslipidemia management clinic.

An alternative to the 1 month dedicated to CVD prevention
is a 3-month (or longer) training in comprehensive cardiac
rehabilitation with at least weekly attendance.
&

Level 2: Additional training in “1 or more areas that enable cardiologists to perform or interpret specific procedures or render more specialized care for specific patients
and conditions.” For prevention, the Task Force identified
no specific competencies for Level II training.
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&

Level 3: For trainees who are interested in seeking expertise to attain program director-level positions in clinical,
research or combined programs. No formal level III training program or curriculum has been identified for CVD
prevention as of yet. Trainees are encouraged to attain
additional (currently non ACGME-accredited) fellowships to achieve level III.

The core competencies in CVD prevention modules (graded by milestones) for trainees were also delineated by the
COCATS 4 Task Force guidelines which included six domains (medical knowledge, patient care and procedural skills,
system-based practice, practice-based learning and improvement, professionalism and interpersonal and communication
skills). Further, a strong emphasis was placed on learning risk
factor modification strategies in curtailing the progression of
subclinical atherosclerosis as well as CHD-associated morbidity and mortality [10••].
As a result, general cardiology fellow in training (FITs) are
mandated to spend at least 1 month of their 36-month training
period in a prevention setting to obtain the minimum level of
expertise in CVD prevention and meet the aforementioned
milestones. Although COCATs level I preventive training is
required of all cardiology FITs [10••], trainees who are interested in pursuing a career in CVD prevention will likely require an additional 1–2 years of training.

Potential Challenges in CVD Prevention Training
The initial challenge in pursuing a career in CVD prevention is
the absence of centralized resources or consolidated catalog of
prospective training opportunities for fellows or residents.
Similarly, there is no central board/society which would allow
certification in preventive cardiology. Furthermore, candidates
who are on a visa may face additional difficulty as their visas
may not be acceptable for training at many of the programs.
Unlike the traditional medicine residencies or ABIM recognized subspecialty fellowships, CVD prevention fellowships do not have an “Electronic Residency Application
Service” (ERAS) like application portal which streamlines
the application process, includes a list of all currently available
programs, and manages application submissions as well as
communication related to interview invitations.
Although several societies provide guidelines and recommendations on management of various aspects of CVD prevention [11–13], there is currently a lack of a formalized curriculum for CVD prevention fellowship training which has been
endorsed uniformly across all societies. Further, the duration of
a CVD prevention fellowship may vary from institution to
institution. Depending on the program, training may be 1 or
2 years and include research and/or clinical time to various
degrees. Most 2-year fellowships include a research year with
focuses including basic science, genetics, translational, and/or
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outcomes/quality improvement. Given the growing need for
this subspecialty in the USA and worldwide, there have been
recent suggestions for ABIM accreditation of preventive cardiology as a fifth subspecialty in cardiology [8••].

Current Programs and Available Certifications
Various training options are available for interested candidates
which may cover (but are not limited to) general topics in
CVD prevention as below:
&
&
&
&
&
&

Lipid and hypertension management strategies for primary and secondary prevention
Obesity management
Cardiac rehabilitation
Cardiovascular genomics
Design and conduct of clinical trials
Biostatistics and epidemiological training in CVD

Pack et al. previously published a consolidated list of 15
such training programs [14]. However, given that this was
published at least 5 years ago, changes in program websites,
application deadlines, and training descriptions are likely. We
have therefore outlined currently existing programs that we
are aware of in Table 1. All programs were contacted to ensure
ongoing training. Furthermore, current contact information is
provided in this updated table.
In addition to these independently funded opportunities in
CVD prevention training, there exists a comprehensive list of
the National Heart Lung and Blood Institute (NHLBI)-funded
Epidemiology and Statistical training programs for MDs and
PhDs interested in CVD prevention on its official website [15].
These programs, which are primarily research-oriented and
aimed towards training predoctoral and postdoctoral applicants,
are an important pathway towards becoming an investigator in
the field of CVD prevention. However, the NIH-funded programs are only open to US citizens or non-citizen nationals or
green card holders and those on temporary or student visas are
generally not eligible to apply for these positions.
We are not certain how many prospective applicants are
familiar with the NHLBI website resources. Therefore, we
have summarized some of these programs in Table 2. A complete list of the NHLBI-funded training programs can also be
found at https://www.nhlbi.nih.gov/research/training/epi-bio.
Given that there is no ACGME accreditation for CVD prevention, the programs are in general sponsored by the local
state medical board. The lack of ownership by a centralized
board for CVD prevention training is a major limiting factor in
formalized learning for this essential subspecialty.
Currently, the National Lipid Association independently controls the American Board of Clinical Lipidology, which provides
a certification in lipidology which is not affiliated with or endorsed by the ABIM. It also provides an annual Masters in

MD
MD

MD, DO,
PhD
MD

MD

Laurence Sperling,
Terry Jacobson
Paul Thompson,
Antonio Fernandez

Kyle Klarich, MD
Stephen L. Kopecky, MD

Arthur Schwartzbard, MD
Eugenia Gianos, MD

James H. O’Keefe, MD

Daniel Duprez, MD, PhD

Clive Rosendorff, MD

Mayo Clinic
Rochester, MN

New York University
New York City, NY

Saint Luke’s Mid America
Heart Institute
Kansas City, KS
University of Minnesota
Minneapolis, MN

MD

Internal medicine

Internal medicine or cardiology

Internal medicine or cardiology

Internal medicine or cardiology

Internal medicine or cardiology

Internal medicine or OB/GYN
or family medicine

Internal medicine or cardiology

1

1

1

1

1–2

2

1–2

1

1–2

1–2

No. of
fellows

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Visa

https://www.dom.umn.edu/divisions/cardiovascular/education/
subspecialties/preventive-cardiology
cvfellow@umn.edu
Indrawattie.naipal@va.gov

https://www.saintlukeshealthsystem.org/preventive-cardiology-fellowship

http://www.med.nyu.edu/medicine/cardiology/education/
fellowship-training-program/advanced-fellowships/
preventive-cardiology-fellowship
ania.coats@nyumc.org

http://medicine.emory.edu/cardiology/index.html
lsperli@emory.edu
https://hartfordhospital.org/health-professionals/education/residenciesfellowships/noninvasive-cardiology-fellowship/applications-contacts
Michelle.Bradby@hhchealth.org
http://www.mayo.edu/mayo-clinic-school-of-graduate-medical-education/
residencies-fellowships/internal-medicine-and-subspecialties/cardiologypreventive-fellowship-minnesota
olson.ashley@mayo.edu

https://www.brown.edu/academics/medical/education/
other-programs/fellowships
debora.mcauliffe@va.gov
http://www.cedars-sinai.edu/Education/Graduate-Medical-Education/
Fellowship-Programs/Womens-Health/
kremsd@cshs.org

https://www.bcm.edu/departments/medicine/sections-divisions-centers/
atherosclerosis-and-vascular-medicine/education/lipid-andatherosclerosis-fellowship
dhunt@bcm.edu

Website/e-mail contact

US citizens, nationals, and green card holders are eligible for all listed programs. These programs also sponsor international medical graduate applicants requiring visas (typically J1), although this is subject
to change

Veterans Affairs Hospital
Bronx
New York City, NY

Internal medicine or cardiology

MD

Noel Bairey-Merz, MD
Prediman K. Shah

Cedars Sinai—Women’s
Heart Disease and
Health Fellowship
Los Angeles, CA
Emory University
Atlanta, GA
Hartford Hospital
Hartford, CT
MD

Internal medicine or cardiology

MD

Wen-Chih Wu, MD
Gaurav Choudhary, MD

Brown University
Providence, RI

Internal medicine or cardiology
or endocrinology

Vijay Nambi, MD PhD
Christie Ballantyne, MD

Baylor College of Medicine
Houston, TX

Prerequisites

Program director/
co-director

Clinical Cardiovascular Disease Prevention Fllowship programs (in alphabetical order) available for trainees considering a career in coronary heart disease prevention

Program name

Table 1
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Wayne Rosamond, MS, PhD
Gerardo Heiss, MD, PhD
Trevor Orchard, MD
Emma Barinas-Mitchell, PhD
Akira Sekikawa, MD, PhD, PhD
David Herrington, MD, MHS

University of North Carolina
Chapel Hill, NC

University of Pittsburgh

Postdoctoral

Postdoctoral

Postdoctoral

Postdoctoral

3

2

4

4 (T-32)
*4–5 spots
(funded through AHA)
8

5

2–3

Number of Fellows

http://www.wakehealth.edu/School/Cardiology/Fellowships/Clinical
-Cardiology-Cardiovascular.htm
dherring@wakehealth.edu

http://www.brighamandwomens.org/research/
depts/medicine/Preventive_Medicine/
pridker@partners.org
http://www.jhsph.edu/academics/postdoctoral-training/
cardiovascular-disease-epidemiology-training-program/index.html
coresh@jhu.edu
http://www.preventivemedicine.northwestern.edu/
education/Post-doc-training/index.html
p-greenland@northwestern.edu
http://prevention.stanford.edu/education/fellowship/criteria.html
Alana.koehler@stanford.edu
http://cvdepit32.ucsd.edu/
mcriqui@ucsd.edu
nsrogers@ucsd.edu
https://sph.unc.edu/epid/epidemiology-research/cardiovascularepidemiology-research/
Wayne_Rosamond@unc.edu
http://www.cvdtraining.pitt.edu/
ejb4@pitt.edu

Website Email Contact

AHA American Heart Association

T-32 grant positions are only available for US citizens, non-citizen nationals or, Green Card holders. Programs may also include predoctoral positions which are beyond the scope of this article; full list
available at https://www.nhlbi.nih.gov/research/training/epi-bio

Wake Forrest University
Winston-Salem, NC

Michael Criqui, MD, MPH
Bess Marcus, PhD

MD, PhD

Philip Greenland, MD,
Mercedes Carnethon, PhD
Martha Daviglus, MD, PhD
Christopher Gardner, PhD
MD, PhD

Postdoctoral

Josef Coresh, MD, PhD
Elizabeth Selvin, PhD

Stanford Hospital
Stanford, CA
University of California
San Diego, CA

Postdoctoral

Paul Ridker, MD, MPH

Brigham and Women’s Hospital/
Harvard Medical School
Boston, MA
Johns Hopkins Bloomberg School
of Public Health
Baltimore, MD
Northwestern University
Chicago, IL

Pre requisite

Program Director/ Co Director

Postdoctoral NIH-funded T-32 grant fellowship programs in cardiovascular disease epidemiology and prevention

Program Name

Table 2
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Clinical Lipidology course for interested trainees and other
healthcare providers. Other societies which provide board certifications or online continuing medical education (CME) opportunities include The American Society of Preventive Cardiology
(Online CME courses), American Society of Hypertension
(Specialist in Clinical Hypertension Certification and Certified
Hypertension Clinician Certificate), American Obesity Society
(American Board of Obesity Management Certification), and
American Association of Diabetes Educators (Board
Certification in Advanced Diabetes Management). More information on these courses are detailed on the respective organization’s official websites.

subspecialty of cardiovascular disease training. Leading professional organizations like the American College of
Cardiology (ACC) and American Heart Association (AHA)
can collaborate with other organizations focused on CVD prevention to provide resources and help develop CVD prevention training programs. There are several ways ACC/AHA can
collaborate with the CVD training programs which include
(and may not be limited to) creating a central resource list
for training opportunities which is readily accessible for
trainees and providing resources to institutions with CVD fellowship programs, such as offering online curriculum focused
on preventative training (lipid disorder management, smoking
cessation, resistant hypertension, and cardiac rehabilitation).

Directions for the Future
Potential Structure of Fellowship Training
Prevention of CVD remains one of the major goals for the scientific and healthcare community. Therefore, CVD prevention (both
primary and secondary) requires dedicated attention and training.
However, preventive cardiology is a subspecialty that is at times,
lost between clinical internal medicine, endocrinology, and cardiology with no clear champion. Resources and formalized structure
in CVD prevention training are scant. Although the ACC
COCATS guidelines provide a general framework and recommendations for basic training in CV prevention that is required of all
training programs in cardiovascular medicine, several programs
still lack the requirements for basic training in CVD prevention.
Moving forward, it is important for central educational
bodies like the ABIM to recognize CVD prevention as a
Table 3 Suggested cardiovascular
disease prevention training
program outline

Although the structure of currently available fellowships in
CVD prevention depends on the specific home institution, moving forward, an ACGME-approved curriculum will be beneficial for comprehensive training. In our opinion, a fellowship
program for CVD prevention should aim to train both clinicians
and physician-scientists who will advance the field. Shapiro
et al. have recently suggested what preventive cardiology fellowships should include (8). Table 3 illustrates our proposed
structure for a CVD prevention fellowship training program.
The clinician track may encompass a 1-year clinical training
where FITs train in lipid, diabetes, hypertension, obesity, and
cardiac rehabilitation which will aid them with the management

Track

Clinical Track

Physician-Scientist Track

Duration (years)
Clinical Exposurea
• Lipid clinic
• Hypertension

1
3 or more half day clinics per week

1–2
1–2 half-day clinics per week

• Diabetes management
• Cardiac rehabilitation
• Dietician/lifestyle management
• Heart failureb Prevention
Adolescent preventive
medicine clinic
Research training
Basic research methodology and
statistics understanding
> 1 publication per year

Conferences/Journal Club

Weekly

Atleast 1 project/publication
in the year
Grant writing training
Additional; MPH/MSCR Course
Degree/CSTP Course
Weekly

CSTP Clinician-Scientist Training Program, MPH Masters in Public Health, MSCR Masters in Science in Clinical
Research
a

Clinical exposure includes multiple clinics including but not limited to the mentioned clinical training themes

b

Heart Failure Prevention is, at present, not an established clinical model
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of complex cases referred by other specialists. For the physicianscientist track, training will be geared towards producing researchers in CVD prevention. The physician-scientist track
FITs would benefit from clinical exposure during the course of
their fellowship. However, more time would likely be allocated
to learning research methodology and grant writing skills.
In the future, another aspect of a CVD prevention fellowship could be dedicated to primordial prevention in addition to
primary and secondary prevention. Collaboration between
adult and pediatric cardiologists could allow FITs to spend
time acquiring skills necessary for evaluation of children/teenagers/adolescents who are at high risk for developing CVD
and associated risk factors like diabetes and hypertension.

Conclusions
In today’s era, knowledge of the various aspects of CVD prevention is becoming increasingly relevant. CVD prevention is
fundamental to global cardiovascular care, and there is room
for improvement in training cardiology FITs and other trainees
interested in this field. The central educational bodies should
take important further steps such as recognizing CVD prevention as a subspecialty of cardiovascular medicine as well as
creating and endorsing a central portal for the training opportunities in this field. These measures can aid trainees in furthering their clinical and research expertise in this area and
provide networking opportunities with faculty and other
trainees with a focus in CVD prevention. The ACC/AHA
can significantly help further this mission. It is our belief
and hope that implementation of such measures will encourage and prepare more leaders in the field of CVD prevention.

Compliance with Ethics Guidelines
Conflict of Interest Anum Saeed and Kaustubh Dabhadkar declare no
conflict of interest. Salim S. Virani receives an honorarium from the
American College of Cardiology as Associate Editor for Innovations for
ACC.org. Peter H. Jones has been a scientific consultant to Amgen and to
Sanofi/Regeneron the past 12 months. Vijay Nambi was on a regional
advisory board for Sanofi and is named on provisional patent no.
61721475 entitled “Biomarkers to Improve Prediction of Heart Failure
Risk” filed by Baylor College of Medicine and Roche. Christie M.
Ballantyne has received grant/research support (all paid to institution,
not individual) from Abbott Diagnostic, Amarin, Amgen, Eli Lilly,
Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostic, SanofiSynthelabo, NIH, AHA, and ADA; has been a consultant for Abbott
Diagnostics, Amarin, Amgen, Astra Zeneca, Boehringer Ingelheim, Eli
Lilly, Esperion, Ionis, Matinas BioPharma Inc., Merck, Novartis, Pfizer,
Regeneron, Roche Diagnostic, and Sanofi-Synthelabo; and is named on
provisional patent no. 61721475 entitled “Biomarkers to Improve
Prediction of Heart Failure Risk” filed by Baylor College of Medicine
and Roche.
Human and Animal Rights and Informed Consent This article does not
contain any studies with human or animal subjects performed by any of
the authors.

Page 7 of 7 35

References
Papers of particular interest, published recently, have been
highlighted as:
•• Of major importance
1.

Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R,
et al. Heart disease and stroke Statistics-2017 update: a report from
the American Heart Association. Circulation. 2017;135:e146–603.
2. Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save
money? Health economics and the presidential candidates. N Engl J
Med. 2008;358:661–3.
3. Nambi V, Liu X, Chambless LE, de Lemos JA, Virani SS, Agarwal
S, et al. Troponin T and N-terminal pro-B-type natriuretic peptide: a
biomarker approach to predict heart failure risk—the atherosclerosis risk in communities study. Clin Chem. 2013;59:1802–10.
4. Pokharel Y, Gosch K, Nambi V, Chan PS, Kosiborod M, Oetgen
WJ, et al. Practice-level variation in statin use among patients with
diabetes: insights from the PINNACLE registry. J Am Coll Cardiol.
2016;68:1368–9.
5. Onorato A, Sturm AC. Heterozygous familial hypercholesterolemia. Circulation. 2016;133:e587–9.
6. Fernandez-Friera L, Fuster V, Lopez-Melgar B, et al. Normal LDLcholesterol levels are associated with subclinical atherosclerosis in
the absence of risk factors. J Am Coll Cardiol. 2017;70:2979–91.
7. Nambi V, Bhatt DL. Primary prevention of atherosclerosis: time to
take a selfie? J Am Coll Cardiol. 2017;70:2992–4.
8.•• Shapiro MD, Fazio S. Setting the agenda for preventive cardiology.
Circ Res. 2017;121:211–3. A comprehensive paper which described an potential preventive cardiology service for practical
purposes and preventive cardiology training outline.
9. Pack QR, Keteyian SJ, McBride PE, Weaver WD, Kim HE. Current
status of preventive cardiology training among United States cardiology fellowships and comparison to training guidelines. Am J
Cardiol. 2012;110:124–8.
10.•• Smith SC Jr, Bittner V, Gaziano JM, et al. COCATS 4 task force 2:
training in preventive cardiovascular medicine. J Am Coll Cardiol.
2015;65:1754–62. An important document published by the
American College of Cardiology on the requirements for
trainees for achieving milestones in cardiovascular disease prevention during their general cardiovascular disease fellowship
training.
11. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH,
et al. National lipid association recommendations for patientcentered management of dyslipidemia: part 1—full report. J Clin
Lipidol. 2015;9:129–69.
12. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. ACC expert
consensus decision pathway on the role of non-statin therapies for
LDL-cholesterol lowering in the management of atherosclerotic
cardiovascular disease risk: a report of the American College of
Cardiology Task Force on clinical expert consensus documents. J
Am Coll Cardiol. 2016;68:92–125.
13. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT,
Fonseca VA, Garber AJ, et al. American Association of Clinical
Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23:1–87.
14. Pack QR, Keteyian SJ, McBride PE. Subspecialty training in preventive cardiology: the current status and discoverable fellowship
programs. Clin Cardiol. 2012;35:286–90.
15. NHLBI. National Heart Lung and blood institute, National
Research Service Award Programs in cardiovascular epidemiology,
biostatistics, and Prev Med 2017.

